Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Investigational New Drugs
Erschienen in: Investigational New Drugs 4/2011

01.08.2011 | PRECLINICAL STUDIES

Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism

verfasst von: Mirth T. Hoyt, Rahul Palchaudhuri, Paul J. Hergenrother

Erschienen in: Investigational New Drugs | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Summary

Cribrostatin 6 is a quinone-containing natural product that induces the death of cancer cell lines in culture, and its mechanism of action and scope of activity are unknown. Here we show that cribrostatin 6 has broad anticancer activity, potently inducing apoptotic cell death that is not preceded by any defined cell cycle arrest. Consistent with this data, we find that cribrostatin 6 treated cells have large amounts of reactive oxygen species (ROS) and, based on transcript profiling experiments and other data, this ROS generation is likely the primary mechanism by which cribrostatin 6 induces apoptosis. Given the success of certain ROS producers as anticancer agents, cribrostatin 6 has potential as a novel chemotherapeutic agent.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468PubMedCrossRef
2.
Begleiter A (1983) Cytocidal action of the quinone group and its relationship to antitumor activity. Cancer Res 43:481–484PubMed
3.
4.
Li V-S, Choi D, Tang M, Kohn H (1996) Concerning in vitro mitomycin-DNA alkylation. J Am Chem Soc 118:3765–3766CrossRef
5.
Le SB, Hailer MK, Buhrow S et al (2007) Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 282:8860–8872PubMedCrossRef
6.
Lu HR, Zhu H, Huang M et al (2005) Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 68:983–994PubMedCrossRef
7.
Pelicano H, Carney D, Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97–110PubMedCrossRef
8.
Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73:2047–2058PubMedCrossRef
9.
Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66:4863–4871PubMedCrossRef
10.
Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR (2008) Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res 36:e100PubMedCrossRef
11.
Belcourt MF, Penketh PG, Hodnick WF et al (1999) Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc Natl Acad Sci USA 96:10489–10494PubMedCrossRef
12.
Pettit GR, Collins JC, Herald DL et al (1992) Isolation and structure of cribrostatins 1 and 2 from the blue marine sponge Cribrochalina sp. Can J Chem 70:1170–1175CrossRef
13.
Pettit GR, Collins JC, Knight JC et al (2003) Antineoplastic agents. 485. Isolation and structure of cribrostatin 6, a dark blue cancer cell growth inhibitor from the marine sponge Cribrochalina sp. J Nat Prod 66:544–547PubMedCrossRef
14.
Pettit GR, Knight JC, Collins JC et al (2000) Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4, and 5 from the republic of maldives cribrochalina species. J Nat Prod 63:793–798PubMedCrossRef
15.
Sandoval IT, Davis RA, Bugni TS, Concepcion GP, Harper MK, Ireland CM (2004) Cytotoxic isoquinoline quinones from sponges of the genus Petrosia. Nat Prod Res 18:89–93PubMedCrossRef
16.
Nakahara S, Kubo A, Mikami Y, Ito J (2006) Synthesis of cribrostatin 6 and its related compounds. Heterocycles 68:515–520CrossRef
17.
Pettit RK, Fakoury BR, Knight JC et al (2004) Antibacterial activity of the marine sponge constituent cribrostatin 6. J Med Microbiol 53:61–65PubMedCrossRef
18.
Nakahara S, Kubo A (2004) Synthesis of cribrostatin 6. Heterocycles 63:2355–2362CrossRef
19.
Nakahara S, Kubo A (2003) Catalytic hydrogenation of 8-acyloxy-1-cyanoisoquinoline and synthesis of 9-methoxy-9-deethoxy-cribrostatin 6. Heterocycles 60:2717–2725CrossRef
20.
21.
Knueppel D, Martin SF (2009) Total synthesis of cribrostatin 6. Angew Chem Int Ed Engl 48:2569–2571PubMedCrossRef
22.
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112–1116PubMedCrossRef
23.
McGrath T, Center MS (1988) Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 48:3959–3963PubMed
24.
25.
26.
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284PubMedCrossRef
27.
Horiatis D, Wang Q, Pinski J (2004) A new screening system for proliferation-independent anticancer agents. Cancer Lett 210:119–124PubMedCrossRef
28.
Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768PubMedCrossRef
29.
Siu WY, Arooz T, Poon RY (1999) Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 250:131–141PubMedCrossRef
30.
Jainchill JL, Todaro GJ (1970) Stimulation of cell growth in vitro by serum with and without growth factor relation to contact inhibition and viral transformation. Exp Cell Res 59:137–146PubMedCrossRef
31.
Baguley BC, Falkenhaug EM (1978) The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Res 5:161–171PubMedCrossRef
32.
Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338–350PubMedCrossRef
33.
Palchaudhuri R, Hergenrother PJ (2007) DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 18:497–503PubMedCrossRef
34.
Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789–802PubMedCrossRef
35.
Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173–184PubMed
36.
Bolognese A, Correale G, Manfra M, Esposito A, Novellino E, Lavecchia A (2008) Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4, 3′-thieno[2, 3-g]quinoline]-tetraones and spiro[thieno[2, 3-g]quinoline-3, 5′-[1, 2, 4]triazinane]-tetraones with potent antiproliferative activity. J Med Chem 51:8148–8157PubMedCrossRef
37.
Suzuki K, Yahara S, Kido Y, Nagao K, Hatano Y, Uyeda M (1998) Topostatin, a novel inhibitor of topoisomerases I and II produced by Thermomonospora alba strain No. 1520. II. Physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 51:999–1003
38.
Yoshinari T, Yamada A, Uemura D et al (1993) Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490–494PubMed
39.
Chene P, Rudloff J, Schoepfer J et al (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 9:1PubMedCrossRef
40.
Meng LH, Zhang JS, Ding J (2001) Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 62:733–741PubMedCrossRef
41.
Park HJ, Lee HJ, Lee EJ et al (2003) Cytotoxicity and DNA topoisomerase inhibitory activity of benz[f]indole-4, 9-dione analogs. Biosci Biotechnol Biochem 67:1944–1949PubMedCrossRef
42.
Tzu-Hao W, Hsin-Shih W, Yung-Kwei S (2000) Paclitaxel-induced cell death. Cancer 88:2619–2628CrossRef
43.
Jordan P, Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229–1235PubMedCrossRef
44.
Tsao YP, D’Arpa P, Liu LF (1992) The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52:1823–1829PubMed
45.
Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMed
46.
Ling YH, el-Naggar AK, Priebe W, Perez-Soler R (1996) Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49:832–841PubMed
47.
Kletsas D, Barbieri D, Stathakos D et al (1998) The highly reducing sugar 2-deoxy-D-ribose induces apoptosis in human fibroblasts by reduced glutathione depletion and cytoskeletal disruption. Biochem Biophys Res Commun 243:416–425PubMedCrossRef
48.
Sheikh MS, Garcia M, Zhan Q, Liu Y, Fornace AJ Jr (1996) Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ 7:1599–1607PubMed
49.
Durrant D, Richards JE, Walker WT, Baker KA, Simoni D, Lee RM (2008) Mechanism of cell death induced by cis-3, 4′, 5-trimethoxy-3′-aminostilbene in ovarian cancer. Gynecol Oncol 110:110–117PubMedCrossRef
50.
Criddle DN, Gillies S, Baumgartner-Wilson HK et al (2006) Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem 281:40485–40492PubMedCrossRef
51.
Kirshner JR, He S, Balasubramanyam V et al (2008) Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319–2327PubMedCrossRef
52.
Place AE, Suh N, Williams CR et al (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9:2798–2806PubMed
53.
Cervantes A, Pinedo HM, Lankelma J, Schuurhuis GJ (1988) The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett 41:169–177PubMedCrossRef
54.
Cathcart R, Schwiers E, Ames BN (1983) Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Biochem 134:111–116PubMedCrossRef
55.
Lamb J (2007) The connectivity map: a new tool for biomedical research. Nat Rev Cancer 7:54–60PubMedCrossRef
56.
Hieronymus H, Lamb J, Ross KN et al (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321–330PubMedCrossRef
57.
Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935PubMedCrossRef
58.
Shibahara S (2003) The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. Tohoku J Exp Med 200:167–186PubMedCrossRef
59.
Pietsch EC, Chan JY, Torti FM, Torti SV (2003) Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 278:2361–2369PubMedCrossRef
60.
Ferris CD, Jaffrey SR, Sawa A et al (1999) Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1:152–157PubMedCrossRef
61.
Nagai T, Kikuchi S, Ohmine K et al (2008) Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. J Cell Biochem 104:680–691PubMedCrossRef
62.
Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163–1170PubMedCrossRef
63.
Marcu L, Olver I (2006) Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 1:71–79PubMedCrossRef
64.
Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6–20PubMedCrossRef
65.
Matsunaga, T, Tsuji, Y, Kaai, K, et al (2010) Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-009-1292-5
66.
Laux I, Nel A (2001) Evidence that oxidative stress-induced apoptosis by menadione involves Fas-dependent and Fas-independent pathways. Clin Immunol 101:335–344PubMedCrossRef
67.
Kang YH, Yi MJ, Kim MJ et al (2004) Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64:8960–8967PubMedCrossRef
68.
Lee CS, Park SY, Ko HH, Han ES (2004) Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells. Biochem Pharmacol 68:1857–1867PubMedCrossRef
69.
Siu WY, Yam CH, Poon RYC (1999) G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett 461:299–305PubMedCrossRef
70.
Matzno S, Yamaguchi Y, Akiyoshi T, Nakabayashi T, Matsuyama K (2008) An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull 31:1270–1273PubMedCrossRef
71.
Emil Mladenov ITBA (2007) Activation of the S phase DNA damage checkpoint by mitomycin C. J Cell Physiol 211:468–476PubMedCrossRef
72.
Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579–591PubMedCrossRef
73.
Berkenblit A, Eder JP Jr, Ryan DP et al (2007) Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13:584–590PubMedCrossRef
74.
Tuma RS (2008) Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst 100:11–12PubMedCrossRef
75.
Hauschild A, Eggermont AM, Jacobson E, O’Day SJ (2009) Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). J Clin Oncol (Meeting Abstracts) 27:LBA9012
Metadaten
Titel
Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism
verfasst von
Mirth T. Hoyt
Rahul Palchaudhuri
Paul J. Hergenrother
Publikationsdatum
01.08.2011
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2011
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9390-x

Weitere Artikel der Ausgabe 4/2011

Investigational New Drugs 4/2011 Zur Ausgabe

PHASE III STUDIES

Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients

PRECLINICAL STUDIES

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats

PRECLINICAL STUDIES

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

PHASE I STUDIES

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

PRECLINICAL STUDIES

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

PRECLINICAL STUDIES

Anticancer activity and mode of action of titanocene C

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise